When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

The transaction – announced on Christmas Eve – comes after WuXi AppTec has been thrust into the US political spotlight as a ...

China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about ...

The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.

The future of the BIOSECURE Act was made more uncertain over the weekend after senators left the legislation out of a pivotal defence budget bill. The omission means the act, which intends to ...

In Ireland, WuXi Biologics has sold a new vaccines plant to Merck & Co. for €500 million ($521 million). The New Jersey ...

The US House earlier this year resoundingly voted in favor of the blacklist legislation, dubbed the Biosecure Act, and a bipartisan group in the Senate supported the measure as well. But senior ...

The Biosecure Act was left out of a key US defence bill that passed in the House last week, in a major win for Chinese CDMOs. Shares in WuXi AppTec (Shanghai, China) opened 10.5% higher on ...

Wuxi Biologics (WXXWY) plans to sell its Irish vaccine facility to Merck (MRK) for around $500M ahead of potential U.S. legislation that would ...

The acquisition from Wuxi Biologics, the embattled CDMO named in the BIOSECURE Act, marks another expansion of Merck’s ...

Which brings me to legislation, which recently passed the U.S. House of Representatives, called the BIOSECURE Act. This bill was developed to block specific Chinese companies from getting access ...